Myrtelle Announces Presentation of Positive 6-month Post-Treatment Data in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the American Society of Gene and Cell Therapy 26th Annual Meeting
Wakefield, Mass., May, 16th, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
May 16, 2023
This article is featured on another website.
Go to article
August 9, 2023
Landmark paper in Nature Communications highlights continued advances in Evox Therapeutics’s proprietary exosome engineering platform
Novel scaffold proteins for improved drug loading published by Evox co-founder
August 9, 2023
Landmark paper in Nature Communications highlights continued advances in Evox Therapeutics’s proprietary exosome engineering platform
Novel scaffold proteins for improved drug loading published by Evox co-founder